Working… Menu

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02619617
Recruitment Status : Terminated (Novartis decision based on Cohort 1 results)
First Posted : December 2, 2015
Results First Posted : January 13, 2020
Last Update Posted : January 5, 2021
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this study was to determine if SOM230 is safe and effective for the treament of cluster headache.

Condition or disease Intervention/treatment Phase
Cluster Headache - Episodic and Chronic Drug: SOM230 Drug: Placebo Phase 2

Detailed Description:
The purpose of this non-confirmatory study was to determine if SOM230 has adequate efficacy and safety to warrant further clinical development in cluster headache (CH). This study was a sequential design of SOM230 vs. Placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 Subcutaneous (s.c.)
Actual Study Start Date : October 31, 2016
Actual Primary Completion Date : September 25, 2018
Actual Study Completion Date : September 25, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache
Drug Information available for: Pasireotide

Arm Intervention/treatment
Experimental: SOM230 0.9mg
cohort 2
Drug: SOM230
The study evaluated SOM230 vs Placebo

Drug: Placebo
The study evaluated SOM230 vs Placebo

Experimental: SOM230 1.5 mg
cohort 1
Drug: SOM230
The study evaluated SOM230 vs Placebo

Drug: Placebo
The study evaluated SOM230 vs Placebo

Primary Outcome Measures :
  1. Number of Participants With Headache Response (PD Analysis Set) [ Time Frame: 30 minutes post dose ]
    Defined as very severe, severe, or moderate pain before dosing that becomes mild or nil at 30 minutes post-dosing

Secondary Outcome Measures :
  1. Number of Participants Who Were Pain Free at 30 Minutes Post Dose [ Time Frame: 30 mins post dose ]
    Participants who were pain free 30 minutes after dosing and reporting improvement of associated autonomic symptoms (for example, lacrimation, blushing, pupil constriction, etc.) over time was tabulated by dose.

  2. Change in Hemoglobin Values From Screening to End of Study [ Time Frame: screening and end of study, up to 9 days after treatment ]
    Change in hemoglobin values from screening and end of study

  3. Pulse Rate [ Time Frame: screening and end of study, up to 9 days after treatment ]
    Vital signs by treatment and time point

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is male or female age 18-65 inclusive.
  • Written informed consent must be obtained before any assessment is performed.
  • Subjects must have established diagnosis of episodic cluster headaches (CH) or chronic CH, averaging 2-6 headache attacks per day each lasting at least 45 minutes without treatment, not to exceed 6 attacks per day within the last year.
  • Able to communicate well with the investigator, to understand and comply with the requirements of the study, as well as accepting NOT to share any study information through social media during their participation in the study.
  • Subject is able to self-inject medication subcutaneously or have the assistance of a partner on an out-patient basis.

Exclusion Criteria:

  • Subjects that have a history of greater than 6 CH attacks per day within the last year.
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during the duration dosing of the study treatment. Or men who are sexually active with women of child bearing potential, unless the male subjects always use condoms during the study.
  • History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study.
  • Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations.
  • A history of clinically significant heart diseases, ECG abnormalities, continued use of drugs known to prolong QTc during the study conduct, or any of the following ECG abnormalities at screening or baseline:

    • QTcF > 450 msec (males)
    • QTcF > 460 msec (females)
  • Uncontrolled diabetes as evidenced by screening HbA1c > 8.0%
  • A positive Hepatitis B surface antigen or Hepatitis C test result.
  • A positive pregnancy test or lactating mothers.
  • History of drug or alcohol abuse within the 12 months prior to dosing other than prescription medications to manage their CH attacks, or evidence of such abuse as indicated by the laboratory assays conducted during screening.
  • Significant acute illness which has not resolved within two (2) weeks prior to initial dosing.
  • Any surgical or medical condition which might significantly jeopardize the subject's safety in case of participation in the study. The Investigator should make this determination in consideration of the subject's medical history and/or clinical or laboratory evidence of any of the following:
  • Liver disease or liver injury as indicated by abnormal liver function tests. ALT (SGPT), AST (SGOT), γ-GT, alkaline phosphatase and serum bilirubin will be tested.
  • ALT must be within the normal range
  • Serum bilirubin must not exceed 1.2 x ULN
  • γ-GT, AST and alkaline phosphatase must not exceed 2 x ULN [If necessary, laboratory testing may be repeated on one occasion (as soon as possible) prior to treatment, to rule out any laboratory error]
  • Acute cholecystitis or symptomatic cholelithiasis in subjects without H/O cholecystectomy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02619617

Layout table for location information
United States, California
Novartis Investigative Site
Culver City, California, United States, 90230
United States, Pennsylvania
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19107
Novartis Investigative Site
Königstein im Taunus, Taunus, Germany, 61462
United Kingdom
Novartis Investigative Site
London, United Kingdom, SE5 9RS
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by Novartis ( Novartis Pharmaceuticals ):
Study Protocol  [PDF] March 14, 2018
Statistical Analysis Plan  [PDF] November 9, 2018

Additional Information:
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT02619617    
Other Study ID Numbers: CSOM230Y2201
First Posted: December 2, 2015    Key Record Dates
Results First Posted: January 13, 2020
Last Update Posted: January 5, 2021
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Cluster Headache
Patient Diary collection of headache pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Cluster Headache
Neurologic Manifestations
Trigeminal Autonomic Cephalalgias
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs